HINCKLEY GREGORY K
Known title: DirectorCIK: 0001239182
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Truist Securities raises SI-BONE price target to $25. Truist Securities kept its existing rating on SI‑BONE and lifted its price target to $25. The new target sits near the midpoint of the nine‑analyst consensus range of $20 to $32, and slightly above the current 52‑week high of $21.89. This adjustment suggests the firm sees further upside potential for the company.
Transaction History
| BIO | ▲ Buy | Option Exercise | 407 | $0 | 4/21/2026 | View on chart |
| SIBN | ▲ Buy | Option Exercise | 3,085 | $18K | 4/7/2026 | View on chart |
| SIBN | ▲ Buy | Grant | 8,675 | $0 | 6/5/2025 | View on chart |
| BIO | ▲ Buy | Option Exercise | 308 | $0 | 4/22/2025 | View on chart |
| SIBN | ▲ Buy | Grant | 8,791 | $0 | 6/26/2024 | View on chart |
| SIBN | ▲ Buy | Grant | 4,866 | $0 | 6/9/2023 | View on chart |
| SIBN | ▲ Buy | Grant | 8,324 | $0 | 6/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth
The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth. The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.